Latest developments in tryptophan metabolism: Understanding its role in B cell immunity

Moffett, 2003, Tryptophan and the immune response, Immunol. Cell Biol., 81, 247, 10.1046/j.1440-1711.2003.t01-1-01177.x Gostner, 2020, Tryptophan metabolism and related pathways in psychoneuroimmunology: the impact of nutrition and lifestyle, Neuropsychobiology, 79, 89, 10.1159/000496293 Fuchs, 1991, Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection, Immunol. Lett., 28, 207, 10.1016/0165-2478(91)90005-U Favre, 2010, Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease, Sci. Transl. Med., 2, 10.1126/scitranslmed.3000632 Jenabian, 2014, Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection, Clin. Exp. Immunol., 178, 102, 10.1111/cei.12396 Jenabian, 2015, Montreal primary infection and slow progressor study groups, immunosuppressive tryptophan catabolism and gut mucosal dysfunction following early HIV infection, J. Infect. Dis., 212, 355, 10.1093/infdis/jiv037 Chen, 2014, Anti-retroviral therapy decreases but does not normalize indoleamine 2,3-dioxygenase activity in HIV-infected patients, PLoS One, 9 Gaardbo, 2015, Increased tryptophan catabolism is associated with increased frequency of CD161+Tc17/MAIT cells and lower CD4+ T-Cell count in HIV-1 infected patients on cART after 2 years of follow-up, J. Acquir. Immune Defic. Syndr. 1999, 70, 228, 10.1097/QAI.0000000000000758 Bipath, 2015, The kynurenine pathway activities in a sub-Saharan HIV/AIDS population, BMC Infect. Dis., 15, 346, 10.1186/s12879-015-1087-5 Dagenais-Lussier, 2016, Kynurenine reduces memory CD4 T-Cell survival by interfering with interleukin-2 signaling early during HIV-1 infection, J. Virol., 90, 7967, 10.1128/JVI.00994-16 Boasso, 2007, HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells, Blood, 109, 3351, 10.1182/blood-2006-07-034785 Planès, 2013, HIV-1 Tat protein induces the production of IDO in human monocyte derived-dendritic cells through a direct mechanism: effect on T cells proliferation, PLoS One, 8, 10.1371/journal.pone.0074551 Widner, 2000, Enhanced tryptophan degradation in systemic lupus erythematosus, Immunobiology, 201, 621, 10.1016/S0171-2985(00)80079-0 Schroecksnadel, 2003, Increased degradation of tryptophan in blood of patients with rheumatoid arthritis, J. Rheumatol., 30, 1935 Pertovaara, 2007, Indoleamine 2.,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season, Clin. Exp. Immunol., 150, 274, 10.1111/j.1365-2249.2007.03480.x Perl, 2015, Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin, Metabolomics Off. J. Metabolomic Soc., 11, 1157 Aeinehband, 2016, Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms, Brain Behav. Immun., 51, 47, 10.1016/j.bbi.2015.07.016 Lim, 2017, Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression, Sci. Rep., 7, 41473, 10.1038/srep41473 Åkesson, 2018, Kynurenine pathway is altered in patients with SLE and associated with severe fatigue, Lupus Sci. Med., 5, 10.1136/lupus-2017-000254 Gaetani, 2020, Host and microbial tryptophan metabolic profiling in multiple sclerosis, Front. Immunol., 11, 157, 10.3389/fimmu.2020.00157 Vyboh, 2015, HIV and the gut microbiota, partners in crime: breaking the vicious cycle to unearth new therapeutic targets, J. Immunol. Res., 9 Amobi, 2017, Tryptophan catabolism and cancer immunotherapy targeting IDO mediated immune suppression, 129 Prendergast, 2018, Indoleamine 2,3-dioxygenase and its therapeutic inhibition in cancer, 175, 10.1016/bs.ircmb.2017.07.004 Ohue, 2019, Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?, Cancer Sci., 110, 2080, 10.1111/cas.14069 Benavente, 2019, Contribution of IDO to human respiratory syncytial virus infection, J. Leukoc. Biol., 106, 933, 10.1002/JLB.4RU0219-051RR Ritprajak, 2019, Current paradigms of tolerogenic dendritic cells and clinical implications for systemic lupus erythematosus, Cells, 8, 1291, 10.3390/cells8101291 Zhai, 2020, Immunosuppressive IDO in cancer: mechanisms of action, animal models, and targeting strategies, Front. Immunol., 11, 1185, 10.3389/fimmu.2020.01185 Brown, 2020, Intestinal dysbiosis and tryptophan metabolism in autoimmunity, Front. Immunol., 11, 1741, 10.3389/fimmu.2020.01741 Meireson, 2020, IDO expression in cancer: different compartment, different functionality?, Front. Immunol., 11, 10.3389/fimmu.2020.531491 Jenabian, 2013, Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers, PLoS One, 8, 10.1371/journal.pone.0078146 Barnas, 2019, B cell targeted therapies in autoimmune disease, Curr. Opin. Immunol., 61, 92, 10.1016/j.coi.2019.09.004 Wekerle, 2017, B cells in multiple sclerosis, Autoimmunity, 50, 57, 10.1080/08916934.2017.1281914 Sarvaria, 2017, B cell regulation in cancer and anti-tumor immunity, Cell. Mol. Immunol., 14, 662, 10.1038/cmi.2017.35 Largeot, 2019, The B-side of cancer immunity: the underrated tune, Cells, 8, 10.3390/cells8050449 Inoue, 2018, Generation of memory B cells and their reactivation, Immunol. Rev., 283, 138, 10.1111/imr.12640 Moir, 2017, B-cell responses to HIV infection, Immunol. Rev., 275, 33, 10.1111/imr.12502 Shen, 2015, Suppressive functions of B cells in infectious diseases, Int. Immunol., 27, 513, 10.1093/intimm/dxv037 Wang, 2020, B cell development and maturation, Adv. Exp. Med. Biol., 1254, 1, 10.1007/978-981-15-3532-1_1 Liu, 2020, Regulation of humoral immune responses and B cell tolerance by the IgM fc receptor (FcμR), Adv. Exp. Med. Biol., 1254, 75, 10.1007/978-981-15-3532-1_7 Villa, 2017, Aryl hydrocarbon receptor is required for optimal B‐cell proliferation, EMBO J., 36, 116, 10.15252/embj.201695027 Rodriguez, 2013, CYP1A1 regulates breast cancer proliferation and survival, Mol. Cancer Res. MCR., 11, 780, 10.1158/1541-7786.MCR-12-0675 Vaidyanathan, 2017, The aryl hydrocarbon receptor controls cell-fate decisions in B cells, J. Exp. Med., 214, 197, 10.1084/jem.20160789 Muramatsu, 2000, Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme, Cell, 102, 553, 10.1016/S0092-8674(00)00078-7 Revy, 2000, Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2), Cell, 102, 565, 10.1016/S0092-8674(00)00079-9 Fagarasan, 2003, Intestinal IgA synthesis: regulation of front-line body defences, Nat. Rev. Immunol., 3, 63, 10.1038/nri982 Munn, 2013, Indoleamine 2.,3 dioxygenase and metabolic control of immune responses, Trends Immunol., 34, 137, 10.1016/j.it.2012.10.001 Mellor, 2017, Indoleamine 2.,3-dioxygenase and tolerance: where are we now?, Front. Immunol., 8, 10.3389/fimmu.2017.01360 Scott, 2009, The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity, J. Immunol., 182, 7509, 10.4049/jimmunol.0804328 Shinde, 2015, B cell–intrinsic IDO1 regulates humoral immunity to t cell–Independent antigens, J. Immunol., 195, 2374, 10.4049/jimmunol.1402854 Merlo, 2017, 25 Merlo, 2020, B-cell-Targeted 3DNA nanotherapy against indoleamine 2,3-dioxygenase 2 (IDO2) ameliorates autoimmune arthritis in a preclinical model, Clin. Pathol., 13, 10.1177/2632010X20951812 Merlo, 2020, Differential roles of IDO1 and IDO2 in t and B cell inflammatory immune responses, Front. Immunol., 11, 1861, 10.3389/fimmu.2020.01861 Piper, 2019, Aryl hydrocarbon receptor contributes to the transcriptional program of IL-10-producing regulatory B cells, Cell Rep., 29, 1878, 10.1016/j.celrep.2019.10.018 Jaufmann, 2019, Human monocytic myeloid‐derived suppressor cells impair B‐cell phenotype and function in vitro, Eur. J. Immunol., 16 Arneth, 2019, Impact of B cells to the pathophysiology of multiple sclerosis, J. Neuroinflammation, 16, 128, 10.1186/s12974-019-1517-1 Li, 2019, Mesenchymal stromal cells attenuate multiple sclerosis via IDO-dependent increasing the suppressive proportion of CD5+ IL-10+ B cells, Am. J. Transl. Res., 11, 5673 van Wissen, 2002, IFN-γ amplifies IL-6 and IL-8 responses by airway epithelial-like cells via indoleamine 2,3-dioxygenase, J. Immunol., 169, 7039, 10.4049/jimmunol.169.12.7039 Guillemin, 2005, Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons, Glia, 49, 15, 10.1002/glia.20090 Mehraj, 2015, Tryptophan catabolism in chronic viral infections: handling uninvited guests, Int. J. Tryptophan Res. IJTR, 8, 41 Bonezi, 2020, Flavivirus-mediating B cell differentiation into antibody-secreting cells in humans is associated with the activation of the tryptophan metabolism, Front. Immunol., 11, 20, 10.3389/fimmu.2020.00020 Morris, 2017, The role of the microbial metabolites including tryptophan catabolites and short chain fatty acids in the pathophysiology of immune-inflammatory and neuroimmune disease, Mol. Neurobiol., 54, 4432, 10.1007/s12035-016-0004-2 Gao, 2018, Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism, Front. Cell. Infect. Microbiol., 8, 13, 10.3389/fcimb.2018.00013 Sun, 2020, Tryptophan (Trp) modulates gut homeostasis via aryl hydrocarbon receptor (AhR), Crit. Rev. Food Sci. Nutr., 60, 1760, 10.1080/10408398.2019.1598334 Roager, 2018, Microbial tryptophan catabolites in health and disease, Nat. Commun., 9, 3294, 10.1038/s41467-018-05470-4 Chen, 2006, Feedback control of morphogenesis in fungi by aromatic alcohols, Genes Dev., 20, 1150, 10.1101/gad.1411806 Elleuch, 2010, Bioactive secondary metabolites from a new terrestrial Streptomyces sp. TN262, Appl. Biochem. Biotechnol., 162, 579, 10.1007/s12010-009-8808-4 Jin, 2015, The effect of tryptophol on the bacteriophage infection in high-temperature environment, Appl. Microbiol. Biotechnol., 99, 8101, 10.1007/s00253-015-6674-2 Narayanan, 1976, Beta-indoleethanol and beta-indolelactic acid production by Candida species: their antibacterial and autoantibiotic action, Antimicrob. Agents Chemother., 9, 375, 10.1128/AAC.9.3.375 Bommarius, 2013, A family of indoles regulate virulence and Shiga toxin production in pathogenic E. coli, PLoS One, 8, 10.1371/journal.pone.0054456 Holst, 2007, The physiology of glucagon-like peptide 1, Physiol. Rev., 87, 1409, 10.1152/physrev.00034.2006 de Mello, 2017, Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study, Sci. Rep., 7, 46337, 10.1038/srep46337 Zelante, 2013, Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22, Immunity, 39, 372, 10.1016/j.immuni.2013.08.003 Cervantes-Barragan, 2017, Lactobacillus reuteri induces gut intraepithelial CD4+CD8αα+ T cells, Science, 357, 806, 10.1126/science.aah5825 Cheng, 2015, Aryl hydrocarbon receptor activity of tryptophan metabolites in young adult mouse colonocytes, Drug Metab. Dispos. Biol. Fate Chem., 43, 1536, 10.1124/dmd.115.063677 Hubbard, 2015, Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles, Sci. Rep., 5, 12689, 10.1038/srep12689 Lowe, 2014, Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production, PLoS One, 9, 10.1371/journal.pone.0087877 Schiering, 2017, Feedback control of AHR signalling regulates intestinal immunity, Nature, 542, 242, 10.1038/nature21080 Rosser, 2014, Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production, Nat. Med., 20, 1334, 10.1038/nm.3680 Rosser, 2020, Microbiota-derived metabolites suppress arthritis by amplifying aryl-hydrocarbon receptor activation in regulatory B cells, Cell Metab., 31, 837, 10.1016/j.cmet.2020.03.003 Platten, 2019, Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond, Nat. Rev. Drug Discov., 18, 379, 10.1038/s41573-019-0016-5 Le Naour, 2020, Trial watch: IDO inhibitors in cancer therapy, OncoImmunology, 9 Ouyang, 2020, Treating from the inside out: relevance of fecal microbiota transplantation to counteract gut damage in GVHD and HIV infection, Front. Med. (Lausanne), 7, 421, 10.3389/fmed.2020.00421 Löb, 2009, Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?, Nat. Rev. Cancer, 9, 445, 10.1038/nrc2639 Ramadoss, 2004, Use of 2-azido-3-[125I]iodo-7,8-dibromodibenzo-p-dioxin as a probe to determine the relative ligand affinity of human versus mouse aryl hydrocarbon receptor in cultured cells, Mol. Pharmacol., 66, 129, 10.1124/mol.66.1.129 Blasco, 2020, The specific metabolome profiling of patients infected by SARS-COV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine metabolism, Sci. Rep., 10, 16824, 10.1038/s41598-020-73966-5 Bouças, 2020, Why severe COVID-19 patients are at greater risk of developing depression: a molecular perspective, Neuroscientist Cai, 2020, Kynurenic acid underlies sex-specific immune responses to COVID-19, Infect. Dis. (except HIV/AIDS) Essa, 2020, Possible role of tryptophan and melatonin in COVID-19, Int. J. Tryptophan Res., 13, 10.1177/1178646920951832 Turski, 2020, AhR and IDO1 in pathogenesis of Covid-19 and the “Systemic AhR Activation Syndrome:” a translational review and therapeutic perspectives, Restor. Neurol. Neurosci., 38, 343 Kimhofer, 2020, Integrative modeling of quantitative plasma lipoprotein, metabolic, and amino acid data reveals a multiorgan pathological signature of SARS-CoV-2 infection, J. Proteome Res., 19, 4442, 10.1021/acs.jproteome.0c00519 Thomas, 2020, COVID-19 infection results in alterations of the kynurenine pathway and fatty acid metabolism that correlate with IL-6 levels and renal status, Infect. Dis. (except HIV/AIDS) Belladonna, 2020, Potential benefits of tryptophan metabolism to the efficacy of Tocilizumab in COVID-19, Front. Pharmacol., 11, 959, 10.3389/fphar.2020.00959